X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Research and development continues long after a medicine is initially approved

By Jocelyn Ulrich  |    February 1, 2022
The government’s flawed price setting plan under the Build Back Better Act will significantly upend the biopharmaceutical research and development (R&D) process, risking important advances in patient...   Read More

Four things to know from IQVIAs latest report

By Katie Koziara  |    October 29, 2021
As the debate in Washington continues on drug pricing, it’s important that policymakers take into account what is actually happening in the market for medicines. Here are four things about medicine...   Read More

H.R. 3 threatens access to medicines, future innovation and American jobs

By Gabby Migliara  |    May 4, 2021
In the last election, voters made clear that they want quality, affordable health coverage that works when they need it and lower out-of-pocket costs for medicines. And we can achieve those goals,...   Read More

New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England

By Nicole Longo  |    December 10, 2020
In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to balance...   Read More

No matter how you look at it, the Most Favored Nation rule is bad policy

By Nicole Longo  |    December 1, 2020
Last month, the administration released the “Most Favored Nation” (MFN) rule, which allows foreign governments to decide the value of Part B medicines, while also likely limiting seniors’ access to...   Read More

Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D

By Nicole Longo  |    November 16, 2020
Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...   Read More

ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19

By Andrew Powaleny  |    August 4, 2020
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...   Read More

Executive order threatens R&D when we need it most to fight COVID-19

By Nicole Longo  |    July 30, 2020
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...   Read More

The continued imperative to protect U.S. innovation worldwide

By Chris Moore  |    April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...   Read More

Three reasons the Administration should abandon its International Pricing Index proposal

By Nicole Longo  |    January 31, 2020
According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American patients...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates